ArticleThe Journal of veterinary medical science2026
Two-stage reconstruction using basic fibroblast growth factor-impregnated artificial dermis and acellular fish skin graft in a dog with distal extremity soft tissue sarcoma.
Article in The Journal of veterinary medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 13-year-old Chihuahua presented with a distal forelimb soft tissue sarcoma and underwent surgical excision. To close the resulting large skin defect, a two-stage approach was performed using a basic fibroblast growth factor (bFGF)-impregnated artificial dermis composed of collagen gelatin sponge (CGS), followed by application of an acellular fish skin graft (FSG). After 10 days of bFGF-impregnated CGS application, uniform granulation tissue had formed, and an FSG was subsequently applied. Complete epithelialization was achieved 25 days after FSG placement without additional grafting. At 320 days postoperatively, no postoperative complications or local recurrence were observed. However, given the potential risk of promoting residual tumor cell proliferation, local bFGF use in malignant tumor-associated wounds should be restricted to carefully selected cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.